Core Viewpoint - The article discusses allegations of potential fraud regarding the collagen content in a product from Juzhibio, specifically questioning the accuracy of the ingredient labeling and the detection methods used to measure collagen levels [1][2]. Group 1: Allegations and Testing - A social media influencer raised concerns about the collagen content in Juzhibio's product, claiming that the detected amount of collagen was significantly lower than what was stated on the label [1][2]. - The influencer used high-precision HPLC amino acid quantification methods and reported that the detected collagen content was only 0.0177%, while the product label suggested that collagen should be present in amounts greater than 0.1% [2]. - The influencer highlighted that glycine, a key amino acid in collagen, was not detected in the sample, which contradicts established knowledge that glycine constitutes one-third of collagen's amino acid residues [2]. Group 2: Company Response - In response to the allegations, Juzhibio's brand, Kefu Mei, issued a statement asserting that multiple tests conducted in accordance with industry standards showed collagen content exceeding 0.1% [5][7]. - The company provided testing results from five samples taken on May 24, showing collagen levels of 0.27% to 0.28% [7]. - Kefu Mei criticized the influencer's testing methods as not being recognized by industry standards and claimed that the influencer did not request the original collagen raw materials for testing [9]. Group 3: Background and Financial Performance - Juzhibio, known as the "first stock of recombinant collagen," has rapidly grown to become the largest beauty and skincare company in Hong Kong by market capitalization, reaching HKD 82.1 billion as of May 23 [11]. - The company's revenue for 2024 was reported at CNY 5.539 billion, reflecting a year-on-year growth of 57.17%, while net profit reached CNY 2.062 billion, up 42.06% [14]. - The founders of Juzhibio recently became the richest individuals in Shaanxi province, with a combined stock value exceeding CNY 45 billion [13].

Core Viewpoint - The beauty blogger "Dr. Big Mouth" accused Giant Biological (02367.HK) of serious fraud regarding its Kefu Mei collagen essence, claiming that the actual content of recombinant collagen is only 0.0177% in the best-selling product, and that the key component "glycine" is missing [2][3][10]. Group 1: Accusations and Responses - The blogger questioned the legality of labeling recombinant collagen as a non-trace component when its actual content is below the regulatory threshold of 0.1% [3][10]. - Giant Biological issued a statement firmly denying the allegations, asserting that multiple tests showed collagen content greater than 0.1%, contradicting the blogger's claims [12][14]. - The company emphasized its adherence to scientific ethics and regulatory compliance, stating that all products are rigorously tested and verified [12][14]. Group 2: Product Composition Concerns - The blogger raised concerns about the absence of glycine in a product claiming to contain recombinant collagen, questioning the validity of calling it "recombinant collagen" [5][9]. - There were also questions about the marketing of a dipeptide molecule as "Mini small molecule collagen," suggesting potential misuse of scientific terminology [7]. Group 3: Market Performance and Investor Sentiment - Despite the controversies, Giant Biological has seen significant growth, reporting a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.07%, and a net profit of 2.062 billion yuan, up 42.06% [22]. - The company has gained substantial attention from investors, with several funds heavily investing in its stock, indicating strong market confidence [24].

Core Viewpoint - The article discusses allegations against Juzhi Biotechnology regarding potential falsification of collagen content in their product, specifically the "Human-Like Recombinant Collagen" serum, following a social media post by a blogger who claims to have conducted tests revealing significantly lower collagen levels than stated on the product label [1][2]. Group 1: Allegations and Testing - A social media influencer conducted tests using high-precision HPLC methods and reported that the detected collagen content was only 0.0177%, which raises questions about the accuracy of the product's ingredient label [1][2]. - The blogger highlighted that the product's ingredient list includes "soluble collagen" as a primary component, which should be above 0.1% according to cosmetic labeling regulations, yet the test results suggest otherwise [2]. - The absence of glycine, a key amino acid in collagen, in the test results further supports the allegations of misrepresentation [2]. Group 2: Company Response - Juzhi Biotechnology's brand, Kefu Mei, issued a statement claiming that multiple tests conducted in accordance with industry standards showed collagen content exceeding 0.1%, with specific results of 0.27%, 0.27%, and 0.28% from samples taken on May 24 [5][8]. - The company criticized the blogger's testing methods as not being recognized by industry standards and stated that the blogger did not request the original collagen material for testing [9]. - Kefu Mei announced plans to engage multiple authoritative third-party testing agencies for further verification of their products [9]. Group 3: Background and Market Position - Juzhi Biotechnology, known for its brands Kefu Mei and Keli Jin, has become the largest beauty and skincare company in Hong Kong by market capitalization, reaching HKD 82.1 billion as of May 23 [13]. - The company reported a revenue of CNY 5.539 billion for 2024, reflecting a year-on-year growth of 57.17%, with a net profit of CNY 2.062 billion, up 42.06% [15]. - The founder of Juzhi Biotechnology recently became the richest person in Shaanxi province, with a stock value exceeding CNY 450 billion [15].

Core Viewpoint - The article discusses the evolution of the "medical-research co-creation" trend in the Chinese beauty market, highlighting how brands like La Roche-Posay are leveraging scientific research to differentiate themselves and achieve significant sales growth, particularly in the context of the brand's 50th anniversary [2][4]. Group 1: Brand Performance and Market Position - La Roche-Posay has achieved over €7 billion in sales, marking a significant milestone for L'Oréal's dermatological division, and has become the third-largest skincare brand globally and the most recommended by dermatologists [2][4]. - The brand's unique heritage, rooted in the therapeutic properties of its thermal spring water, has been a key factor in its success, with a history dating back to the 14th century [7][9]. - The brand has submitted 180 research papers and actively participates in global dermatology conferences, reinforcing its position as a leader in skincare science [12][19]. Group 2: Research and Development - La Roche-Posay has a strong commitment to scientific research, having pioneered several innovations in skincare, including the first sunscreen with anti-UVA properties in 1987 and the first microbiome research in 2011 [10][12]. - The brand collaborates with dermatologists and medical experts to develop products that address real skin issues, emphasizing a holistic approach to skincare that includes emotional and psychological aspects [13][14]. Group 3: Market Strategy in China - Since entering the Chinese market in 2001, La Roche-Posay has positioned itself as a pioneer in scientific skincare, rapidly becoming the third-largest market for the brand globally [15][24]. - The brand's sales in China are projected to exceed ¥2.3 billion in 2024, reflecting a 12% year-on-year growth, driven by high repurchase rates of key products [15][24]. - La Roche-Posay has established a robust "medical-research co-creation" system in China, resulting in significant product innovations tailored to local consumer needs [21][24]. Group 4: Social Responsibility and Community Engagement - The "Blue Ribbon" initiative launched in 2022 aims to support skin health for cancer patients, showcasing the brand's commitment to social responsibility and community engagement [26][27]. - La Roche-Posay actively participates in educational campaigns and collaborations with local medical institutions to raise awareness about skin health issues related to cancer treatment [26][27]. Group 5: Consumer Trends and Brand Positioning - The article highlights a shift in consumer behavior towards more informed and rational purchasing decisions, with an increasing focus on ingredient transparency and product efficacy [29][31]. - La Roche-Posay's branding emphasizes a consistent message of professionalism and care, resonating with consumers who prioritize both effectiveness and a human touch in skincare [28][31].

Core Insights - The article emphasizes the growing importance of "barrier repair" in the beauty industry, particularly in response to skin issues arising from modern lifestyles such as stress and lack of sleep [2][5][11] - The "Barrier Repair" market is experiencing significant growth, with a 58% year-on-year increase in product registrations in the first eight months of 2024, indicating a shift from niche concept to essential need [2][11] - The success of the "Skin Barrier Case Competition" initiated by the brand has established it as a benchmark for clinical research in the cosmetics industry, promoting a scientific approach to skincare [3][12] Market Trends - The report highlights that the number of registered repair products reached 4,159 in the first eight months of 2024, with a growth rate exceeding 177% in April 2024 alone [2][11] - The competition has attracted over 800 dermatology experts and has received more than 1,011 real application cases, covering over 20 types of skin issues [6][12] Brand Contributions - The brand has maintained double-digit growth for several years, driven by its focus on barrier repair and innovative research initiatives [3][11] - The introduction of dual tracks in the competition for both adults and children aims to address the unique needs of pediatric skin care, reflecting the brand's commitment to comprehensive skin health [8][19] Industry Impact - The competition has significantly influenced clinical research innovation, improved treatment standardization, and fostered collaboration across academia and industry [12][14] - The brand's approach to integrating treatment and skincare through the use of moisturizers as a fundamental part of therapy has been recognized as a pioneering model in the industry [14][19] Future Strategies - The brand plans to enhance its product offerings by launching five new personal care products by the end of 2024, focusing on diverse consumer needs [19][21] - The brand aims to expand its reach among younger consumers, particularly the Z generation, by emphasizing the efficacy and value of its products [24][25]

Core Viewpoint - The article highlights the conflict between Huaxi Biological and several brokerage firms that support Juzi Biological, criticizing the notion that sodium hyaluronate is outdated and emphasizing the ongoing relevance of hyaluronic acid in the beauty and medical aesthetics industry [1][3]. Company Performance - Huaxi Biological's market capitalization has significantly decreased from over 140 billion yuan in 2021 to approximately 25 billion yuan currently, while Juzi Biological's stock has surged nearly 70% in 2024, elevating its founders to the status of the richest individuals in Shaanxi [2]. - In 2024, Huaxi Biological reported its worst performance since going public, with annual revenue of 5.371 billion yuan, a decline of 11.6% year-on-year, and a net profit of 164 million yuan, down 72.27% [2]. - Juzi Biological, in contrast, has shown robust growth since 2019, with 2024 revenue reaching 5.539 billion yuan, a year-on-year increase of 57.17%, and a net profit of 2.062 billion yuan, up 42.06% [2]. Market Trends - The market is increasingly favoring the field of recombinant collagen due to its excellent biocompatibility and biodegradability, with projections indicating that the collagen-based skincare market may surpass that of hyaluronic acid by 2026, with a compound annual growth rate of 52.6% [3]. - Despite the rise of recombinant collagen, hyaluronic acid remains irreplaceable in the medical aesthetics sector, particularly in filling procedures, and Huaxi Biological continues to hold a competitive edge in this area [3]. Industry Dynamics - Several brokerage firms, including Huafu Securities and Debon Securities, have retracted their reports that were criticized by Huaxi Biological, indicating the contentious nature of the market's perception of recombinant collagen [4]. - The development of recombinant collagen is still in its early stages, with high raw material costs and insufficient research on its applications, suggesting that both hyaluronic acid and recombinant collagen may coexist in the market to meet diverse consumer needs [4].

作者 | 莫奈 编辑 | 江江 你也许不了解重组胶原蛋白，但大概率听过"可复美面膜"。这款年销售额达到45亿元的爆款面膜，正是 巨子生物旗下的王牌。 2001年，完成了专利申请的范代娣与丈夫严建亚创立了"巨子生物"，从此踏入了科研成果转化的道路。 这一路颇为艰辛，但夫妻两人托举出了一家大型生物科技企业。 2001年，范代娣与丈夫严建亚创立了"巨子生物" 视觉 | 顾芗 大学副校长+首富——当两个身份关联到一起的时候，难免给人无限遐想。 范代娣就是拥有这样两个身份的一位女性。 今年，"211大学"西北大学迎来了新任副校长。4月3日，陕西省政府官网最新一批人事任免通知显示，从 今年4月1日起，任命范代娣为西北大学副校长。在此之前，她曾担任西北大学化工学院院长的职务。 | | | | | | | 请输入关键字 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 智能推荐: | 秦创原 | 营商环境 | 招考招录 | 创新发展 | | 首页 | 省政府 | 得长 | 新闻 | 政策 | ...

Core Insights - The news highlights the controversy surrounding Fan Daidi, the vice president of Northwest University, who became the richest person in Shaanxi through her role as a co-founder of the Hong Kong-listed company, Giant Bio (2367.HK), which has a market value of HKD 90.5 billion as of May 15 [2] - The intersection of academic authority and capital interests raises questions about the ability of university leaders to balance public responsibilities with private wealth, exposing deep-seated contradictions in the field of industry-academia-research transformation [2][10] Company Performance - Giant Bio's revenue reached CNY 5.538 billion in 2024, a year-on-year increase of 57.2%, with a net profit of CNY 2.061 billion, up 42.4%, and a gross margin of 82.1% [4] - The brand "Kefumei" generated CNY 4.542 billion in revenue, contributing 87.04% to the total revenue growth of Giant Bio, with its revenue soaring from CNY 289 million in 2019 to CNY 2.788 billion in 2023 [4] - The Chinese recombinant collagen market is projected to grow from CNY 18.5 billion in 2022 to CNY 108.3 billion by 2027, with Giant Bio leading this growth through its flagship brand [4] Competitive Advantages - Giant Bio's competitive edge lies in its proprietary library of over 40 types of collagen and its strong synthetic biology platform, making it difficult for competitors to replicate [5] - The company has established industry standards and transparency commitments, which help marginalize weaker competitors and solidify its market position [5][6] Policy and Regulatory Context - The case of Fan Daidi illustrates the interplay between policy design and business acumen, as her career trajectory aligns with the loosening of technology transfer policies in China [5][10] - Giant Bio benefits from a favorable tax rate of 15% and a closed-loop system that converts public research resources into private competitive advantages [6] Ethical Considerations - The blending of public resources and private interests raises concerns about the privatization of public value, particularly given that 63% of Giant Bio's R&D team comes from Northwest University [9][11] - The complex ownership structures employed by Fan Daidi to maintain her business interests while serving as a university administrator challenge the expectations of academic neutrality [11][12]

Group 1 - The trend of refined parenting is emerging as a new generation of parents, primarily those born in the 1990s and 2000s, are driving changes in child-rearing concepts and consumption patterns, leading to an increased demand for children's skincare products [1] - The baby and toddler skincare market in China is expected to reach nearly 50 billion yuan by 2026, with the skincare segment projected to reach 18 billion yuan, expanding from basic cleaning and moisturizing to more functional areas such as sensitive skin, eczema, sun protection, and mosquito repellent [1] - Domestic beauty companies are increasingly entering the baby skincare market, with brands like Jichu launching products that address common skin issues in infants, such as eczema, through patented micro-ecological balance technology [1] Group 2 - Sales of baby skincare products on major e-commerce platforms are reaching new highs, with companies like Shiseido's subsidiary, Up Beauty, launching multiple baby skincare brands, including Red Elephant and Newpage, which reported significant revenue growth [4] - Newpage achieved a revenue of 376 million yuan in 2024, marking a year-on-year growth of 146.3%, while its revenue growth in 2023 was nearly five times [4] - Other brands like Winona Baby and Qichu are also gaining traction, with Winona Baby generating 201 million yuan in revenue in 2024, reflecting a year-on-year increase of 34.03% [4]

作 者丨凌晨 编 辑丨骆一帆 刘雪莹 产业布局与资本裂变并行，范代娣夫妇试图孵化出更多"巨子生物"。 近日， 西北大学副校长范代娣与其丈夫严建亚凭借4 5 7亿元持股市值，折桂新一任陕西首 富。 近两年，巨子生物（0 2 3 6 7 .HK）二级市场表现可以用"疯狂"来形容。上市不足三年，巨子生 物超越毛戈平， 成为港股市值最大的美妆护肤企业， 截至5月1 3日收盘，市值达8 8 3亿港 元。同时，该公司整体毛利首次跨入4 5亿元， 毛利率高达8 2 . 0 9%，被称为"医美茅"。 | | 所有任职企业 5 所有曾任职企业 9 > | | | | | 미 글 퓨 | 飞天眼查 | | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | | 企业名称 | 胆位 | 注册资本 | 成立日期 | 省份地区 | 登记状态 | | 1 | 個美 | 北京恒美生物技术有限公司 | 股东 | 3万人民币 | 2021-06-03 | 北京市 | 存续 | | 2 | 博数 博 | 陕西博淼睿科技有限公司 | 监事,股东 | 3000万人民币 | 2020-12-2 ...